❌

Normal view

Received — 27 May 2026 ⏭

Multi-Omics Identification of Biomarkers for High-Altitude Pulmonary Hypertension

✇(Multiomics OR Omics) AND (Lung OR gastric OR Hepatocellular)
By: Zhe Chen · Linhong Pang · Yidan Zheng · Li Xu · Mingjing Tang · Ziwen Zhao · Tianyu Wang · Jin Li · Yunfei Zhou · Lin Duo · Wenlong Zhu · Zhiling Luo · Fei Li · Da Zhu
26 May 2026 at 18:00

J Cardiovasc Dev Dis. 2026 Apr 30;13(5):195. doi: 10.3390/jcdd13050195.

ABSTRACT

(1) Aim: The incidence of high-altitude pulmonary hypertension (HAPH) has risen in recent years and is expected to continue increasing; however, its diagnosis remains challenging. In this study, we employed proteomics and metabolomics to identify the proteins and metabolic biomarkers that contribute to the development of HAPH. (2) Methods: We applied integrated proteomics and metabolomics to match blood samples from 40 HAPH patients and 40 healthy controls in Yunnan's high-altitude regions to characterize molecular profiles, identify biomarkers, and develop a predictive model. (3) Results: Proteomic analysis identified four proteins (A2IPH7, K1C14, PSME2, SERPINE2) commonly dysregulated in HAPH patients from two high-altitude regions. SERPINE2 was notably downregulated and showed a negative correlation with clinical severity, which was further validated in HAPH rat lung tissues and supported by UK Biobank data for idiopathic PAH. Concurrent metabolomics uncovered 11 shared metabolites, largely acyl fatty acids, enriched in pathways such as unsaturated fatty acid synthesis. Integration of these multi-omics data enabled the development of a robust predictive model. (4) Conclusion: Our study identified key protein and metabolic biomarkers involved in HAPH development, which were validated in animal models. Based on these findings, a predictive model was developed, highlighting SERPINE2 and 11 metabolites as promising targets for the prediction and prevention of HAPH.

PMID:42188081 | DOI:10.3390/jcdd13050195

Multi-Omics Identification of Biomarkers for High-Altitude Pulmonary Hypertension

✇Omics In Lung
By: Zhe Chen · Linhong Pang · Yidan Zheng · Li Xu · Mingjing Tang · Ziwen Zhao · Tianyu Wang · Jin Li · Yunfei Zhou · Lin Duo · Wenlong Zhu · Zhiling Luo · Fei Li · Da Zhu
26 May 2026 at 18:00

J Cardiovasc Dev Dis. 2026 Apr 30;13(5):195. doi: 10.3390/jcdd13050195.

ABSTRACT

(1) Aim: The incidence of high-altitude pulmonary hypertension (HAPH) has risen in recent years and is expected to continue increasing; however, its diagnosis remains challenging. In this study, we employed proteomics and metabolomics to identify the proteins and metabolic biomarkers that contribute to the development of HAPH. (2) Methods: We applied integrated proteomics and metabolomics to match blood samples from 40 HAPH patients and 40 healthy controls in Yunnan's high-altitude regions to characterize molecular profiles, identify biomarkers, and develop a predictive model. (3) Results: Proteomic analysis identified four proteins (A2IPH7, K1C14, PSME2, SERPINE2) commonly dysregulated in HAPH patients from two high-altitude regions. SERPINE2 was notably downregulated and showed a negative correlation with clinical severity, which was further validated in HAPH rat lung tissues and supported by UK Biobank data for idiopathic PAH. Concurrent metabolomics uncovered 11 shared metabolites, largely acyl fatty acids, enriched in pathways such as unsaturated fatty acid synthesis. Integration of these multi-omics data enabled the development of a robust predictive model. (4) Conclusion: Our study identified key protein and metabolic biomarkers involved in HAPH development, which were validated in animal models. Based on these findings, a predictive model was developed, highlighting SERPINE2 and 11 metabolites as promising targets for the prediction and prevention of HAPH.

PMID:42188081 | DOI:10.3390/jcdd13050195

$M^3-Verse$: A "Spot the Difference" Challenge for Large Multimodal Models

✇cs.AI, q-bio.NC updates on arXiv.org
By: Kewei Wei · Bocheng Hu · Jie Cao · Xiaohan Chen · Zhengxi Lu · Wubing Xia · Weili Xu · Jiaao Wu · Junchen He · Mingyu Jia · Ciyun Zhao · Ye Sun · Yizhi Li · Zhonghan Zhao · Jian Zhang · Gaoang Wang
26 May 2026 at 12:00
arXiv:2512.18735v2 Announce Type: replace-cross Abstract: Modern Large Multimodal Models (LMMs) have demonstrated extraordinary ability in static image and single-state spatial-temporal understanding. However, their capacity to comprehend the dynamic changes of objects within a shared spatial context between two distinct video observations, remains largely unexplored. This ability to reason about transformations within a consistent environment is particularly crucial for advancements in the field of spatial intelligence. In this paper, we introduce $M^3-Verse$, a Multi-Modal, Multi-State, Multi-Dimensional benchmark, to formally evaluate this capability. It is built upon paired videos that provide multi-perspective observations of an indoor scene before and after a state change. The benchmark contains a total of 270 scenes and 2,932 questions, which are categorized into over 50 subtasks that probe 4 core capabilities. We evaluate 16 state-of-the-art LMMs and observe their limitations in tracking state transitions. To address these challenges, we further propose a simple yet effective baseline that achieves significant performance improvements in multi-state perception. $M^3-Verse$ thus provides a challenging new testbed to catalyze the development of next-generation models with a more holistic understanding of our dynamic visual world. You can get the construction pipeline from https://github.com/Wal-K-aWay/M3-Verse_pipeline and full benchmark data from https://www.modelscope.cn/datasets/WalKaWay/M3-Verse.
Received — 26 March 2026 ⏭

In vivo generation of anti-BCMA CAR-T cells in relapsed or refractory multiple myeloma: a phase 1 study

✇Nature Medicine
By: Ning An · Di Wang · Peiling Zhang · Jishuai Zhang · Philippe Parone · Jianlin Hu · Yuhan Bao · Li Xu · Haitao Ruan · Ying Wan · Xinyu Wen · Yang Gao · Chunrui Li
25 March 2026 at 08:00

Nature Medicine, Published online: 25 March 2026; doi:10.1038/s41591-026-04244-6

In a phase 1 trial, the in vivo generation of anti-BCMA CAR-T cells by lentiviral delivery was feasible and did not lead to dose-limiting toxicities in five patients with relapsed or refractory multiple myeloma.
Received — 17 February 2026 ⏭

A Deployment-Friendly Foundational Framework for Efficient Computational Pathology

✇cs.AI, q-bio.NC updates on arXiv.org
By: Yu Cai · Cheng Jin · Jiabo Ma · Fengtao Zhou · Yingxue Xu · Zhengrui Guo · Yihui Wang · Zhengyu Zhang · Ling Liang · Yonghao Tan · Pingcheng Dong · Du Cai · On Ki Tang · Chenglong Zhao · Xi Wang · Can Yang · Yali Xu · Jing Cui · Zhenhui Li · Ronald Cheong Kin Chan · Yueping Liu · Feng Gao · Xiuming Zhang · Li Liang · Hao Chen · Kwang-Ting Cheng
17 February 2026 at 13:00
arXiv:2602.14010v1 Announce Type: cross Abstract: Pathology foundation models (PFMs) have enabled robust generalization in computational pathology through large-scale datasets and expansive architectures, but their substantial computational cost, particularly for gigapixel whole slide images, limits clinical accessibility and scalability. Here, we present LitePath, a deployment-friendly foundational framework designed to mitigate model over-parameterization and patch level redundancy. LitePath integrates LiteFM, a compact model distilled from three large PFMs (Virchow2, H-Optimus-1 and UNI2) using 190 million patches, and the Adaptive Patch Selector (APS), a lightweight component for task-specific patch selection. The framework reduces model parameters by 28x and lowers FLOPs by 403.5x relative to Virchow2, enabling deployment on low-power edge hardware such as the NVIDIA Jetson Orin Nano Super. On this device, LitePath processes 208 slides per hour, 104.5x faster than Virchow2, and consumes 0.36 kWh per 3,000 slides, 171x lower than Virchow2 on an RTX3090 GPU. We validated accuracy using 37 cohorts across four organs and 26 tasks (26 internal, 9 external, and 2 prospective), comprising 15,672 slides from 9,808 patients disjoint from the pretraining data. LitePath ranks second among 19 evaluated models and outperforms larger models including H-Optimus-1, mSTAR, UNI2 and GPFM, while retaining 99.71% of the AUC of Virchow2 on average. To quantify the balance between accuracy and efficiency, we propose the Deployability Score (D-Score), defined as the weighted geometric mean of normalized AUC and normalized FLOP, where LitePath achieves the highest value, surpassing Virchow2 by 10.64%. These results demonstrate that LitePath enables rapid, cost-effective and energy-efficient pathology image analysis on accessible hardware while maintaining accuracy comparable to state-of-the-art PFMs and reducing the carbon footprint of AI deployment.
There are no more articles
❌